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A B S T R A C T
Background
Meta-analyses based on individual participant data (IPD-MAs) allow more powerful and uniformly consistent analyses as well as better
characterisation of subgroups and outcomes, compared to those which are based on aggregate data (AD-MAs) extracted from published
trial reports. However, IPD-MAs are a larger undertaking requiring greater resources than AD-MAs. Researchers have compared results
from IPD-MA against results obtained fromAD-MA and reported conflicting findings. We present a methodology review to summarise
this empirical evidence .
Objectives
To review systematically empirical comparisons of meta-analyses of randomised trials based on IPD with those based on AD extracted
from published reports, to evaluate the level of agreement between IPD-MA and AD-MA and whether agreement is affected by
differences in type of effect measure, trials and participants included within the IPD-MA and AD-MA, and whether analyses were
undertaken to explore the main effect of treatment or a treatment effect modifier.
Search methods
An electronic search of the Cochrane Library (includes Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of
Effectiveness, CENTRAL, Cochrane Methodology Register, HTA database, NHS Economic Evaluations Database), MEDLINE, and
Embase was undertaken up to 7 January 2016. Potentially relevant articles that were known to any of the review authors and reference
lists of retrieved articles were also checked.
Selection criteria
Studies reporting an empirical comparison of the results of meta-analyses of randomised trials using IPD with those using AD. Studies
were included if sufficient numerical data, comparing IPD-MA and AD-MA, were available in their reports.
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Data collection and analysis
Two review authors screened the title and abstract of identified studies with full-text publications retrieved for those identified as eligible
or potentially eligible. A ‘quality’ assessment was done and data were extracted independently by two review authors with disagreements
resolved by involving a third author. Data were summarised descriptively for comparisons where an estimate of effect measure and
corresponding precision have been provided both for IPD-MA and for AD-MA in the study report. Comparisons have been classified
according to whether identical effect measures, identical trials and patients had been used in the IPD-MA and the AD-MA, and whether
the analyses were undertaken to explore the main effect of treatment, or to explore a potential treatment effect modifier.
Effect measures were transformed to a standardised scale (z scores) and scatter plots generated to allow visual comparisons. For each
comparison, we compared the statistical significance (at the 5% two-sided level) of an IPD-MA compared to the corresponding AD-
MA and calculated the number of discrepancies. We examined discrepancies by type of analysis (main effect or modifier) and according
to whether identical trials, patients and effect measures had been used by the IPD-MA and AD-MA. We calculated the average of
differences between IPD-MA and AD-MA (z scores, ratio effect estimates and standard errors (of ratio effects)) and 95% limits of
agreement.
Main results
From the 9330 reports found by our searches, 39 studies were eligible for this review with effect estimate and measure of precision
extracted for 190 comparisons of IPD-MA and AD-MA. We classified the quality of studies as ‘no important flaws’ (29 (74%) studies)
or ‘possibly important flaws’ (10 (26%) studies).
A median of 4 (interquartile range (IQR): 2 to 6) comparisons were made per study, with 6 (IQR 4 to 11) trials and 1225 (542 to 2641)
participants in IPD-MAs and 7 (4 to 11) and 1225 (705 to 2541) for the AD-MAs. One hundred and forty-four (76%) comparisons
were made on the main treatment effect meta-analysis and 46 (24%) made using results from analyses to explore treatment effect
modifiers.
There is agreement in statistical significance between the IPD-MA and AD-MA for 152 (80%) comparisons, 23 of which disagreed in
direction of effect. There is disagreement in statistical significance for 38 (20%) comparisons with an excess proportion of IPD-MA
detecting a statistically significant result that was not confirmed with AD-MA (28 (15%)), compared with 10 (5%) comparisons with a
statistically significant AD-MA that was not confirmed by IPD-MA. This pattern of disagreement is consistent for the 144 main effect
analyses but not for the 46 comparisons of treatment effect modifier analyses. Conclusions from some IPD-MA and AD-MA differed
even when based on identical trials, participants (but not necessarily identical follow-up) and treatment effect measures. The average
difference between IPD-MA and AD-MA in z scores, ratio effect estimates and standard errors is small but limits of agreement are wide
and include important differences in both directions. Discrepancies between IPD-MA and AD-MA do not appear to increase as the
differences between trials and participants increase.
Authors’ conclusions
IPD offers the potential to explore additional, more thorough, and potentially more appropriate analyses compared to those possible
with AD. But in many cases, similar results and conclusions can be drawn from IPD-MA and AD-MA. Therefore, before embarking
on a resource-intensive IPD-MA, an AD-MA should initially be explored and researchers should carefully consider the potential added
benefits of IPD.
P L A I N L A N G U A G E S U M M A R Y
Meta-analysis using individual participant data or summary aggregate data
Meta-analysis is a statistical technique to combine results from separate research studies. A meta-analysis can be performed using
summary data published in a study report, referred to as aggregate data (AD), or using data collected on each individual participant
in the study, referred to as individual participant data (IPD). A meta-analysis of individual participant data (IPD-MA) can take longer
and be more expensive than a meta-analysis of aggregate data (AD-MA), but the IPD-MA can be more reliable and can answer much
more detailed questions than an AD-MA.
We searched for studies, published up to 7 January 2016, that compared results of IPD-MA with AD-MA. We found that four times
out of five, similar conclusions can be drawn, but in one out of five cases the two different types of meta-analyses gave different results
and conclusions. As we could not reliably identify when an IPD-MA and AD-MA will differ most using these studies, we recommend
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that an AD-MA should be done first before doing an IPD-MA. If there are shortcomings with the AD-MA, researchers should then
consider the possible benefits of IPD whilst remembering the extra work involved.
B A C K G R O U N D
Description of the methods being investigated
Meta-analysis, a statistical technique to combine results frommul-
tiple studies addressing similar research questions, is most com-
monly undertaken using aggregate data (AD) extracted from pub-
lished trial reports or requested from trialists. Examples of AD
include the number of events and number of patients randomised
in each treatment group, or published treatment effect estimates
such as the odds ratio, risk ratio or hazard ratio. Meta-analyses
based on individual participant data (IPD-MAs), in which data
on all patients in all relevant randomised trials are centrally col-
lected and re-analysed have been proposed as the gold standard
for systematic reviews (Chalmers 1993).
How these methods might work
Compared with aggregate data meta-analysis (AD-MA), IPD-
MAs allow more powerful and uniformly consistent analyses of,
for example, the time to particular outcomes, different patient sub-
groups and complex outcomes, as well as better characterisation
of these subgroups and outcomes. The extended follow-up that
can often be obtained for IPD can also provide an opportunity
to investigate long-term outcomes. However, IPD-MAs are often
more time-consuming and resource intensive than other forms of
review. It is also possible that an IPD review will not be able to ob-
tain suitable data from all relevant studies and will, therefore, not
be able to include these studies fully in the review, which might
lead to bias.
Why it is important to do this review
One of the key issues in the research agenda of the Cochrane In-
dividual Participant Data Meta-analysis Methods Group, and a
long-standing question of interest in evidence synthesis is ‘How do
IPD-MA and AD-MA results differ’? We present a methodology
review of the empirical evidence to address this question. The first
methodological comparison was presented at the Oslo Cochrane
Colloquium in 1995 followed by an early summary of evidence,
presented at the Amsterdam Colloquium in 1997, when five stud-
ies had been identified that were relevant to a comparison of IPD
with published AD (Clarke 1997). Subsequently, a review of 10
studies was presented at a workshop at the Rome Cochrane Col-
loquium in 1999 (Williamson 2000). IPD-MAs of randomised
trials were shown to differ in important ways from MAs based on
published data alone, and the importance of including as much
follow-up as possible on all randomised participants and data from
all relevant trials (not just those that have been published) was con-
firmed. More recently, a review of 70 empirical comparisons from
25 studies was presented in a German doctorate thesis (Mukhtar
2008), concluding that two thirds of the comparisons showed a
tendency to overestimate the effect size and to reduce its precision
by AD-MA in comparison to IPD-MA. However, the differences
between the point estimates of both types of meta-analysis were
small in all comparisons. Indeed, Olkin 1998 and Mathew 1999
have shown that for continuous outcome data the main effect
results from IPD-MA and AD-MA are theoretically identical if
based on identical data from homogenous studies. However, in
practice, the differences between datasets that are used for IPD-
MA and AD-MA are often subtle and it is rarely the case that
datasets are identical. For example, an IPD-MA may re-instate pa-
tients, or may include additional follow-up data, which were not
included in published analyses that are the basis of an AD-MA.
IPD-MAs are becoming more common in medical research
(Ahmed 2012). Numerous empirical studies comparing their re-
sults to corresponding AD-MA results have been undertaken and
reported in the literature. Some of the empirical studies focused on
research relating to randomised trials of healthcare interventions
have conflicting conclusionsmaking it difficult for researchers, and
research funders, to decide whether there are likely to be important
differences between IPD-MA and AD-MA. There is therefore a
need to summarise the existing evidence from empirical studies to
inform researchers and to help identify where future methodology
research may be required. This review attempts this task, based on
a previously published protocol (Clarke 2007).
O B J E C T I V E S
To review systematically empirical comparisons of meta-analyses
of randomised trials based on IPD with those based on AD ex-
tracted from published reports, to evaluate the level of agreement
between IPD-MA and AD-MA and whether agreement is affected
by differences in type of effect measure, trials and participants in-
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cluded within the IPD-MA and AD-MA, and whether analyses
were undertaken to explore the main effect of treatment or a treat-
ment effect modifier.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies reporting an empirical comparison of the results of meta-
analyses using individual participant data (IPD-MA) with those
using aggregate data (AD-MA). Abstracts were included if suffi-
cient numerical data were available comparing IPD-MA and AD-
MA.
Types of data
Meta-analyses of randomised trials.
Types of methods
Meta-analyses in which centrally collected, processed and analysed
data on each participant in each trial (IPD-MA) have been used to
undertake analyses, compared with meta-analyses in which anal-
yses are based on aggregate data (AD-MA) extracted from pub-
lished reports of the trial or supplied by the people responsible
for it. Comparisons of IPD-MA and AD-MA in which the AD
have been calculated from the IPD were included but those in
which the IPD has been estimated or extracted from published
reports were excluded. We included comparisons where IPD-MA
and AD-MA were either based on the same number of studies and
participants or not (i.e. the studies included in the IPD-MA and
AD-MA, although answering the same question, may only par-
tially overlap). However, studies that compared IPD-MA and AD-
MA from independent sets of studies without any overlap (e.g.
to compare results from studies providing IPD with those studies
that did not provide IPD) were excluded. We excluded compar-
isons of network meta-analysis (NMA) and those in which meta-
analysis methods had been used for the synthesis of data from a
single multi-centre randomised trial.
Types of outcome measures
For each study, we summarised the relevant effectmeasure estimate
and corresponding precision for the IPD-MA and the AD-MA.
Any type of outcome measure was included.
Search methods for identification of studies
Up to 7 January 2016, a variety of searches were undertaken.
An electronic search of the Cochrane Library (including Cochrane
Database of Systematic Reviews, Database of Abstracts of Reviews
of Effectiveness, CENTRAL, Cochrane Methodology Register,
HTA database, NHS Economic Evaluations Database), MED-
LINE, and Embase was undertaken in June 2006 followed by
updated searches in May 2009 and January 2016 (Appendix 1).
Potentially relevant articles that were known to any of the review
authors were also added to the list of records to be assessed. Refer-
ence lists of retrieved articles (Horsley 2011) and an unpublished
review by Mukhtar 2008 were cross-checked.
Data collection and analysis
See Contributions of authors for details of authors participating
in screening, data extraction and quality assessment.
The title and abstract of identified studies were initially screened
for inclusion or exclusion by two review authors. Records judged
to be potentially relevant were discussed and we erred on the side
of inclusion if doubt remained after this discussion. Full-text pub-
lications were retrieved for those identified as eligible or poten-
tially eligible and each was assessed independently by two review
authors with any disagreements resolved by involving a third au-
thor.
Studies identified as eligible were distributed amongst pairs of re-
view authors anddata for every studywere extracted independently
by the two review authors in each pair. Any disagreements were
resolved by involving a third author. The data were extracted using
an online data extraction form (Appendix 2) with data stored in an
Excel spreadsheet. We did not systematically contact the authors
of published empirical comparisons.
A ‘quality’ assessment was undertaken by two review authors in-
dependently with disagreements resolved by involving a third au-
thor. In the context of this review, quality was measured in terms
of the fairness of the comparison between IPD-MA and AD-MA.
For example, a study which compares IPD-MA and AD-MA that
were based on very different inclusion criteriamight be expected to
yield a larger discrepancy in results as compared to a study which
compares IPD-MA and AD-MA using similar inclusion criteria.
Similarly, a study which compares IPD-MA and AD-MA under-
taken by the same researchers, using the same outcome definitions
might be expected to yield smaller discrepancies between IPD-
MA and AD-MA than studies in which the IPD-MA and AD-
MA being compared had been done by different researchers using
different outcome definitions.
The following questions were considered in the assessment of each
included study.
1. In your opinion, are the inclusion criteria for the IPD-MA
and AD-MA similar? Yes, No, Unclear
2. Would you describe the quality of this study as: A = No
4Individual participant data meta-analyses compared with meta-analyses based on aggregate data (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
important flaws; B = Possibly important flaws; C = Major flaws?
3. Was the comparison of IPD-MA and AD-MA a main aim
of the study? Yes, No, Unclear
4. Were the IPD-MA and AD-MA done by independent
researchers? Yes, No, Unclear
5. Were the same outcome definitions used for the IPD-MA
and AD-MA? Yes, No, Unclear
Data have been summarised descriptively for comparisons where
an estimate of effect measure (such as the treatment main effect,
interaction term, or subgroup treatment effect) and corresponding
precision have been provided both for IPD-MA and for AD-MA
in the study report.
Comparisons have been classified according to whether identical
effect measures (yes/no) and identical trials and participants (yes/
no) had been used in the IPD-MA and the AD-MA. Compar-
isons were also classified according to whether the analyses were
undertaken to explore the main effect of treatment, or to explore a
potential treatment effect modifier (for example, by fitting a meta-
regression model with AD or by fitting a regression model includ-
ing an interaction between treatment and covariate with IPD).
If a study report presented an IPD-MA compared tomultiple AD-
MAs for the same comparison (e.g. IPD-MA of overall survival
summarised with hazard ratio (HR) compared to multiple AD-
MAs summarised with risk ratios at different time points), each
comparison has been included to reflect alternative scenarios that
may be considered for the AD-MA. Similarly, if a study report pre-
sented comparisons for multiple clinical outcomes, we attempted
to extract data for all comparisons where this was possible.
Following the approach described by Michiels 2005, ratio effect
measures (hazard ratio (HR), risk ratio (RR), rate ratio, odds ratio
(OR)) were transformed to a standardised scale (z scores) by di-
viding the logarithm of the ratio by the respective standard error.
Similarly, weighted mean differences were transformed to a stan-
dardised scale by dividing the difference by the respective standard
error. Scatterplots of these standardised effects of IPD-MA versus
AD-MA were generated to allow visual comparisons, but bearing
inmind the clustering of comparisons that originate from the same
study. For each comparison, the statistical significance (at the 5%
two-sided level) of an IPD-MAwas compared to that for the corre-
sponding AD-MA and we calculated the number of discrepancies.
Bland-Altman agreement statistics (mean of the differences (IPD-
MA - AD-MA) and limits of agreement) between IPD-MA and
AD-MA z scores, log ratio effect measures, and standard errors (of
log ratio effects) were calculated for main effect analyses and treat-
ment effect modifier analyses separately. Sensitivity analyses were
undertaken to explore the effect of clustering of comparisons from
within the same study. For each analysis we selected at random
(with replacement) one comparison from each study, calculated
agreement statistics, repeated the process 250 times and calculated
the mean and standard deviation across the 250 samples.
R E S U L T S
Description of studies
The PRISMA flow diagram is shown in Figure 1. From a total of
9330 articles retrieved by our searches, we found 39 studies that
met the eligibility criteria and extracted an effect estimate (e.g.
odds ratio (OR), hazard ratio (HR)) and measure of precision (e.g.
95% confidence interval (CI), standard error (SE)) for 190 empir-
ical comparisons of IPD-MA and AD-MA. Twenty studies that
mentioned comparing IPD-ADwith AD-MAbut failed to present
sufficient numerical data for their comparison were deemed inel-
igible.
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Figure 1. Study flow diagram.
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Characteristics of the 39 included studies are shown in
Characteristics of included studies. Studies were published as full-
text journal articles (34 (87%)), abstracts (four (10%)), or a letter
(one (3%)). All but one of the studies were published in English
language journals or conference proceedings. The publication date
of studies ranged between 1992 and 2015 with the highest num-
bers published in the late 1990s and early 2000s (Figure 2). Empir-
ical comparisons were made using randomised trials from a vari-
ety of clinical areas. These included oncology (14 (36%)), cardio-
vascular disease (six (15%)), mixed populations (five (13%)), in-
fectious disease (three (8%)), neurology (three (8%)), nephrology
(three (5%)), critical care (two (5%)), rheumatology (one (3%)),
gynaecology/obstetrics (one (3%)), and respiratory disease (one
(3%)). The outcomes examined in the meta-analyses also varied,
with a large number of studies (26 (67%)) including mortality-
related outcomes. The most common type of outcome data was
time-to-event, which was included in 23 (59%) studies. Eight of
these studies had maintained the time-to-event nature of data for
the comparison of IPD-MA and AD-MA (two of these also in-
cluded a binary outcome), whilst 15 studies treated the data as
binary data for the AD-MA. The remaining studies had included
binary data (nine (23%)), continuous data (six (15%)) and count
data (one (3%)) for the outcome measures compared between
IPD-MA and AD-MA.
Figure 2. Year of publication for 39 included studies comparing IPD-MA and AD-MA
The method of analysis used in the IPD-MAs varied (Table 1).
The most common approach, reflecting the most common type
of data analysed, was the stratified log-rank analysis (11 (28%)
studies) and Cox regression model (seven (18%) studies) for time-
to-event outcomes. Four (10%) studies used a logistic regression
model, two (5%) studies used a multilevel Bayesian model, one
(3%) study used a longitudinal model and three (8%) studies used
continuous outcomes regression models. The method of analysis
was unclear in six (15%) studies and five (13%) further studies
provided some limited information about method of analysis (e.g.
mentioning the use of a “random-effects model”, or “two-stage
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approach”).
A median of 4 (inter-quartile range (IQR): 2 to 6) comparisons
were made per study. Identical effect measures had been used in
the IPD-MA and corresponding AD-MA (e.g. an HR was used in
both the IPD-MA and the corresponding AD-MA) in 115 (61%)
comparisons: 59 (31%) based on identical trials and participants,
and 56 (29%) based on different data. Different effect measures
had been used in the IPD-MA and corresponding AD-MA (e.g.
an HR had been used for the IPD-MA and an OR estimated at
a specific time-point in the AD-MA) in 75 (39%) comparisons:
36 (19%) based on identical trials and participants, and 39 (21%)
based on different data. The median number of trials and partici-
pants were 6 (IQR: 4 to 11) and 1225 (542 to 2641), respectively
for the IPD-MAs and 7 (4 to 11) and 1225 (705 to 2541) for the
AD-MAs. The majority of IPD-MAs were based on an equal (103
(54%); 93 (49%)) or a greater (37 (19%); 50 (26%)) number of
trials and participants respectively, compared to the corresponding
AD-MAs (Figure 3). One hundred and forty-four (76%) compar-
isons were made on the main treatment effect meta-analysis and
46 (24%) were made using results from analyses to explore treat-
ment effect modifiers.
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Figure 3. Number of trials and participants in each empirical comparison of IPD-MA and AD-MA
9Individual participant data meta-analyses compared with meta-analyses based on aggregate data (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Risk of bias in included studies
The assessment of quality in individual studies is summarised in
Table 2. The comparison of IPD-MA versus AD-MAwas themain
objective of the publication in 22 (56%) studies. We classified the
quality of studies as either ‘no important flaws’ (29 (74%) studies)
or ‘possibly important flaws’ (10 (26%) studies). The latter was
due to insufficient information provided in abstracts, or lack of
detail regarding the statistical methods for undertaking the IPD-
MA and AD-MA. The IPD-MA and AD-MA were undertaken
by independent groups in 12 (31%) studies, or by the same group
in 24 (62%) studies, with three (8%) studies unclear. The in-
clusion criteria were similar for the IPD-MA and AD-MA in 36
(92%) studies, and similar outcome definitions had been used for
the IPD-MA and AD-MA in 36 (92%) studies, albeit with some
studies using different approaches to analysis and different treat-
ment effect measures. Insufficient details were provided to judge
the similarity of inclusion criteria and outcome definitions in two
(5%) studies (Franzosi 1997; Legg 2003). For 18 (46%) studies,
the empirical comparison of IPD-MA and AD-MA had focused
on the main effect of treatment, whereas four (10%) studies had
compared results of analyses to explore potential treatment effect
modifiers and 17 (44%) studies had included comparisons of both
main effects and effect modifiers (see Table 1).
Effect of methods
Summary of numerical comparisons
There is variability in the agreement between the standardised
effects (computed for comparisons where effect measures were
summarised as hazard ratio (HR), odds ratio (OR), risk ratio (RR),
rate ratio and difference in means) for 174 IPD-MA and AD-
MA comparisons, as shown by the scatter of points around the
line of equality in Figure 4 and Figure 5. Missing data prevented
calculation of standardised effects for 16 comparisons.
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Figure 4. Comparison of standardised effects (z scores - main effect analyses)
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Figure 5. Comparison of standardised effects (z scores - interaction effect analyses)
Across all 190 comparisons, there is agreement on statistical signifi-
cance (assessed at the 5% level) between the IPD-MA andAD-MA
for 152 (80%) comparisons (Table 3). For example, Duchateau
2001 present an IPD-MA of trials of chemotherapy for patients
with head and neck cancer which was based on 8523 patients
(5201 events) with HR of 0.88 (95% CI: 0.83 to 0.93) compared
to an AD-MA based on 5536 patients (3771 events) with a five-
year mortality OR of 0.78 (95% CI: 0.70 to 0.87). For 23 com-
parisons with agreement in statistical significance in which both
IPD-MA and AD-MA were not statistically significant, there is
disagreement in the direction of effect. For example, theMyeloma
1998 IPD-MA based on 20 trials with 4930 patients estimated
an OR of 0.98 (95% CI: 0.92 to 1.04) with an AD-MA estimate
of 1.03 (95% CI: 0.83 to 1.25) based on seven trials with 1703
patients.
There is disagreement on statistical significance for 38 (20%) com-
parisons. For example, Michiels 2005 estimated the HR from an
IPD-MA to be 0.88 (95% CI: 0.78 to 0.99) whereas the OR
from the AD-MA based on identical data was estimated to be 0.84
(95% CI: 0.67 to 1.06). More of these comparisons have a statisti-
cally significant IPD-MA and non-significant AD-MA (28 (15%))
compared with 10 (5%) comparisons with a statistically signif-
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icant AD-MA and non-significant IPD-MA. Alternative graphs
were produced (not shown) by including one randomly selected
comparison per study to remove the potential correlation caused
by including multiple comparisons from within the same study.
The patterns were similar. This pattern of disagreement between
IPD-MA and AD-MA is consistent when considering themain ef-
fect analyses (Table 4; Figure 4). However, for the treatment effect
modifier analyses, although only based on 46 comparisons, the
percentage of comparisons with disagreement in statistical signif-
icance is similarly distributed (Table 4;Figure 5). The breakdown
of data according to whether or not analyses were based on iden-
tical trials and participants, or identical effect measures (Table 5;
Figure 6; Figure 7) suggests that conclusions from IPD-MA and
AD-MA can still differ even when based on identical trials, par-
ticipants (but not necessarily identical follow-up) and treatment
effect measures (top section of Table 5).
Figure 6. Comparison of standardised effects split by data and effect measure (main effect analyses only)
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Figure 7. Comparison of standardised effects split by data and effect measure (interaction effect analyses
only)
Agreement analyses (Table 6) suggest that on average the IPD-MA
z scores are slightly smaller (-0.22) than the AD-MA scores across
main effect analyses but approximately 95% of the time the differ-
ences lie within limits of agreement of (-2.84 to 2.40), a range of
values that includes important differences in both directions. The
average difference in z scores is slightly larger (0.08) for IPD-MA
interaction effect analyses but again with wide limits of agreement
(-2.26 to 2.43). When considering comparisons that focused only
on ratio effect analyses the IPD-MA z scores are on average smaller
for main effect analyses (-0.34) but larger for interaction effect
analyses (0.42) whereas for comparisons that focused on difference
effects, the IPD-MA z scores are on average larger for main effect
analyses (0.20) and smaller for interaction effect analyses (-0.44).
All these differences are close to zero, suggesting that the IPD-MA
and AD-MA give similar results on average, however the limits of
agreement are wide (Table 6).
When considering differences between IPD-MA and AD-MA in
log ratio effect estimates (e.g. log odds ratio IPD-MA - log odds
ratio AD-MA), the differences are again close to zero for main
effect analyses (-0.004 on the log scale or 0.996 on the natural ratio
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scale) and interaction effect analyses (-0.05 on the log scale or 0.95
on the natural ratio scale) suggesting that on average the IPD-MA
and AD-MA effects are similar. However, the limits of agreement
are wide: approximately 95% of the differences in log ratio effects
lie between -0.36 and 0.35 [i.e. (0.70 and 1.42) on the ratio of
ratios scale] for main effect analyses, and approximately 95% of
the differences in log ratio effects lie between -0.78 and 0.69 [i.e.
(0.46 and 1.99) on the ratio of ratios scale] for interaction effect
analyses.
Finally, when considering differences between IPD-MA and AD-
MA in standard errors of log ratio effect estimates (e.g. SE(log odds
ratio IPD-MA) - SE(log odds ratio AD-MA)), the differences are
again close to zero formain effect analyses (-0.015) and interaction
effect analyses (0.012) suggesting that on average the IPD-MA
and AD-MA precision is similar. However, the limits of agreement
are wide: approximately 95% of the differences lie between -0.14
and 0.11 for main effect analyses and even wider (-0.55 to 0.57)
for interaction effect analyses (Table 6).
Sensitivity analyses to examine the effect of clustering of compar-
isons within studies showed that across 250 samples, each includ-
ing one comparison selected at random from each study, the mean
(SD) of the differences in z scores between IPD-MA and AD-MA
was 0.033 (0.199) for main effect analyses and -0.118 (0.279) for
interaction effect analyses. These values are close to zero and the
95% reference range includes our calculated values of -0.22 and
0.08, suggesting that conclusions from our agreement analyses are
robust.
Scatter plots of the difference in standardised effect between IPD-
MA andAD-MAplotted against the difference (IPD-AD) in num-
bers of patients and trials (Figure 8) do not suggest that discrepan-
cies in results expressed as standardised effects between IPD-MA
and AD-MA increase as the differences between numbers of trials
and patients increase.
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Figure 8. Difference in standardised estimates (IPD-AD) versus difference in participants (top panel) and
trials (bottom panel) for 174 main effect and effect modifier analyses (IPD-AD)
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Summary of descriptive conclusions
Table 1summarises the main conclusions made in each study in
terms of a comparison between IPD-MA and AD-MA.
As seen from the summary of numerical comparisons, several stud-
ies concluded that results of IPD-MA and AD-MA were sim-
ilar. For example, original authors wrote “results were consis-
tent between the trial-level and individual patient data analyses”
(Beveridge 2015); “both our pooled analysis and our meta-analysis
showed that fish oil was not efficacious in patients …” (Brouwer
2009); “this finding was consistent in both trial-level and patient-
level analyses” (Kim 2010); “There is no good evidence of any
difference between the results of trials with individual patient data
and those for which published data were used” (Myeloma 1998);
and “AD and IPD meta-analysis obtained very similar results …”
(Saillourglenisson 2000).
Similarly, some studies describe important differences between
IPD-MA and AD-MA. For example, “The IPD analysis revealed a
clinically important and statistically significant difference between
the effect of treatment…which the AD analyses failed to identify”
(Berlin 2002); “The IPD review provides a larger, more significant
estimate of treatment effect than would have been found with a
review based solely on published data. An IPD review can produce
very important results that might not have been obtainable in any
other way” (Clarke 1998); “The IPD and AD results differed sub-
stantially … the size of the treatment effect varied considerably”
(Duchateau 2001); “The IPD and ADmeta-analyses provided dif-
ferent results (in particular, AD consistently yielded greater esti-
mates of a treatment benefit)” (Jeng 1995); “IPD resulted in more
precise estimates of effect with greater statistical significance and
less statistical heterogeneity” (Legg 2003); and “The best evidence
came from the largest meta-analysis based on IPD” (Lukka 2006).
Finally, regardless of whether or not differences were noted in
statistical significance between IPD-MA and AD-MA, a num-
ber of benefits of IPD were described across studies. For exam-
ple, “the availability of data on individual patients permitted the
identification of subgroups more likely to benefit from treatment”
(D’Amico 1998); “The broader IPD analysis allowed exploring
the effects of a variety of covariates” (Fortin 1995); “It is prefer-
able to obtain IPD from all studies to correctly account for the
correlation between repeated observations” (Jones 2009); “Con-
ventional meta-analyses do not allow proper subgroup analyses,
whereas IPD meta-analyses produce more accurate subgroup ef-
fects.” (Koopman 2008); “Individual patient data are essential to
determine the time course of effects on risk of cancer and other
outcomes during trials” (Rothwell 2011); “It is preferable tomodel
individual patient outcome data directly rather than summary
statistics to avoid the assumptions that have to be made regarding
the summary statistics (of normality and known variance). Fur-
thermore, individual patient level covariates can be introduced to
study potential treatment interactions” (Thompson 2001); “The
availability of IPD allowed a thorough investigation into the main
effects of each covariate which was not possible using meta regres-
sion of AD.” (Tudur Smith 2005); and “Collection of the IPD
is made attractive by the potential of meta-regression analyses for
exploring trial-level, therapist-level and patient-level predictors of
the treatment effect and of the random effects” (Walwyn 2015).
D I S C U S S I O N
We have conducted a meta-epidemiological study of articles re-
porting a numerical comparison of meta-analysis results using in-
dividual participant data (IPD) and aggregate data (AD). Due to
the variability across comparisons in effect measures used, com-
parisons were mainly summarised in terms of z scores and dis-
crepancies in statistical significance as a proxy measure for impact
on clinical decisions. Our findings show that conclusions from
IPD-MA and AD-MA can often differ (38 (20%) comparisons) in
terms of statistical significance and therefore potentially different
clinical conclusions can be expected. It was more common for the
IPD-MA to detect a statistically significant difference that was not
confirmed by the AD-MA (28 (15%)), than the reverse in which
a statistically significant difference was found in the AD-MA but
not the IPD-MA (10 (5%)). Of course, within each of the meta-
analyses, other factors, such as size of effect, balancing benefits
and harms, and degree of heterogeneity between trials, would also
be taken into account when making clinical decisions rather than
necessarily focusing purely on statistical significance. The average
difference in z scores, log ratio effect estimates, and standard errors
between IPD-MA and AD-MA were close to zero, but wide limits
of agreement suggest that IPD-MA and AD-MA are not always
similar and sometimes quite different.
Factors that we expected to lead to important differences between
IPD-MA and AD-MAswere higher levels of trial exclusion, higher
levels of patient exclusion, and greater influence of early follow-
up information for some trials in the AD-MA compared with the
IPD-MA. We did not find evidence to suggest that differences in
the number of included trials and participants would necessarily
lead to differences in conclusions, although it is important in some
cases. In fact, results from IPD-MA and AD-MA can differ when
analyses are based on identical trials and participants, and even
identical effect measures. Additional follow-up data for patients
included in the IPD-MA could explain these discrepancies, but a
lack of information across the majority of studies made it difficult
to explore this reliably. Nevertheless, one of the included studies
(Michiels 2005) did specify that the researchers had compared like
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with like, that is, the same trials, participants, and extended follow-
up in each analysis and they still found discrepancies between IPD-
MA and AD-MA, as well as across 128 trial level analyses, when
analyses were based on different effect measures.
Overall, we found that the proportion of significant results is
greater formain effect analyses compared to treatment effectmodi-
fier analyses. This is most likely because meta-analyses have greater
power to detect main effect results as statistically significant com-
pared to treatment effect modifier analyses (Lambert 2002).
We focused this review on studies reporting numerical data for em-
pirical comparisons of IPD-MA against AD-MA. This naturally
implies some type of corresponding AD-MA is possible. However,
IPD is potentially of greatest value in reviews where AD may be
unavailable or limited and hence an AD-MA would not be fea-
sible. Several included studies described additional analyses that
could only be undertaken with IPD. For example, D’Amico 1998,
Koopman 2008 and Pignon 1992 described subgroup analyses
that could only be explored using IPD. Furthermore, studies that
did not present numerical data comparing IPD-MA and AD-MA
but that may have mentioned limitations of previous AD-MAs as
the motivation to conduct an IPD-MA were not eligible. For ex-
ample, Cools 2010 collected IPD as previous AD-MAs had been
“difficult to interpret because of heterogeneity in study design,
patient characteristics, and outcome definition, and have limita-
tions because interpretations are made on the basis of summary
data extracted from published trial reports.” They concluded that
their IPD-MA “provides clinically relevant information about ef-
fectiveness and safety of elective use of HFOV in preterm infants
with respiratory failure, and improves on past AD-MA” (Cools
2010). These additional benefits of IPD-MA are not fully recog-
nised within this current review and further work is required to
quantify this additional information, to allow more in-depth and
standardised analyses of the comparisons.
Potential biases in the review process
The identification of conference abstracts, principally from the
Cochrane Methodology Register because of the handsearching of
conference proceedings (such as the Cochrane Colloquia, System-
atic Reviews Symposia, INAHTA and HTAi annual conferences,
and the annual meetings of the Society for Clinical Trials) that was
used to compile that Register is a strength of this review, because
of the increased comprehensiveness of the process for identifying
studies. However, despite the comprehensive search strategy and
systematic approach to the identification of studies, there is still
a possibility of publication bias with reporting of empirical com-
parisons of IPD-MA and AD-MA being suppressed due to the
lack of interesting differences between the two approaches whilst
a comparison of IPD-MA and AD-MA may be more likely to be
published when there is a discrepant finding.
Although we present a comprehensive systematic review of empir-
ical comparisons of IPD-MA and AD-MA, there are some limita-
tions.
1. We did not systematically contact the authors of published
empirical comparisons but a future update of this review may
develop into a collaborative review, in which the original
researchers will be asked to conduct common analyses of their
data, to allow more in-depth analyses of the comparisons.
2. Multiple comparisons presented for the same study have
been extracted and compared alongside each other, essentially as
independent studies. Whilst results from exploratory analyses
randomly selecting one comparison per study gave similar
conclusions, results incorporating all 190 comparisons should be
considered cautiously because of the potential clustering of
comparisons within studies.
3. We have focused on comparisons of meta-analysis results
from randomised trials. There are examples in the literature of
empirical comparisons based on observational studies (e.g.
Steinberg 1997) where discrepancies between IPD-MA and AD-
MA may be expected to be more extreme than those
discrepancies observed between meta-analysis of randomised
trials.
4. We excluded comparisons of network meta-analysis (NMA)
but acknowledge that a comparison of IPD-NMA against AD-
NMA (e.g. Cope 2012) is an important research question to
address given the value of using IPD for NMA (Donegan 2013).
5. We excluded comparisons that were based solely on
simulated data (e.g. Lambert 2002) because our main objective
was to examine empirical comparisons of data to capture
experiences of what happens in practice.
Agreements and disagreements with other
studies or reviews
Results from our review are comparable to those described by
Mukhtar 2008 in a German Doctorate thesis which included 25
studies with 70 empirical comparisons of IPD-MA and AD-MA
of randomised trials. Our review includes 22 of their 25 included
studies and an additional 17 studies. Three studies included by
Mukhtar were not eligible for our review: one study appeared to
include IPD mixed with AD rather than IPD-MA compared to
AD-MA; one unpublished study did not contain sufficient re-
liable information; and one study mentioned a comparison of
IPD-AD with AD-MA but failed to present sufficient numerical
data. Mukhtar 2008 concluded that two thirds of the comparisons
showed a tendency to overestimate the effect size and to reduce
its precision by MA-APD in comparison to MA-IPD but the dif-
ferences between the point estimates of both types of meta-anal-
ysis were small in all comparisons. In a separate review, Cooper
2009 describe the relative benefits of IPD-MA compared to AD-
MA illustrated by selected studies that have compared the two ap-
proaches. They conclude that when both IPD and AD are equally
available, IPD-MA is superior to AD-MA as IPD permits sub-
group analyses, checking of the data and analyses in the original
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studies, adding new information to the data sets, and the possi-
bility to use different statistical methods. Due to the cost of IPD-
MA and the potential lack of available IPD, they recommend a
strategy using both approaches in a complementary fashion such
that the first step in conducting an IPD-MA would be to conduct
an AD-MA (Cooper 2009).
A U T H O R S ’ C O N C L U S I O N S
Implication for methodological research
Further research, incorporating the benefits and costs of IPD-
MA and extending to IPD-MA of observational studies would
be beneficial to support decisions about when IPD-MA is most
valuable. More research is required on the value of IPD in network
meta-analysis (NMA).
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C H A R A C T E R I S T I C S O F S T U D I E S





Outcomes Renal allograft failure






Outcomes Overall survival, progression-free survival





Outcomes SBP and DBP
Notes Range of study populations with any reported baseline 25OHD level
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Outcomes Time to first confirmed tachyarrhythmia or death




















Notes Head and neck cancer
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Outcomes Pain, fever or both at 3 and 7 days







Notes Non-small cell lung cancer
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Outcomes Death or dependency













Notes Small-cell lung cancer
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Rothwell 2011 (Continued)






















Notes Range of study populations
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Notes Non-small-cell lung cancer
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Outcomes Overall survival, red blood cell transfusions, thrombovascular events






Notes Locally advanced or metastatic colorectal cancer
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Outcomes Respiratory tract infections, pre-eclampsia












Outcomes Mental health symptoms
Notes Counselling in primary care
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Methods and conclusions
Study IPD-MA methods AD-MA methods Main treatment
effect, subgroup analy-
ses, both
Main conclusions of the
study
Berlin 2002 Logistic regression mod-
els, unadjusted and ad-





regression with AD at the
level of treatment arm;
2) weighted least-squares
linear regression with the
log-odds ratio and log




dom-effects. For all these
analyses the same covari-
ates studied in the IPD
analysis were included
Subgroup The IPD analysis re-
vealed a clinically im-
portant and statistically
significant difference be-
tween the effect of treat-
ment among patients
whose PRAwas >=20per
cent (compared to pa-
tients with PRA < 20 per
cent) which the AD anal-
yses failed to identify
Best 2000 Stratified log-rank analy-
sis (fixed-effect)
Risk of death compared
at 6, 12, 18, 24 months
and the risk of disease
progression was com-
pared at 3, 6, 9 and 12
months
Both The results of AD and
IPD meta-analyses were
broadly similar even if
IPD analysis was more
reliable and informative
Beveridge 2015 Two-stage analysis.
For each study, the mean
BP values for each group
at
the final follow-up were
calculated and adjusted
for baseline values us-
ing analysis of covariance







models. For each analy-
sis at the trial level, the
mean change from base-
line to the last follow-up
reported was compared
between groups
Both Results were consistent
between the trial-level
and IPD analyses
Brouwer 2009 Log-rank tests and
Cox proportional hazard
models were used to as-
sess outcomes when con-
Random-ef-
fects model on hazard ra-
tios (HRs) from the indi-
vidual studies
Both Both our pooled analy-
sis and our meta-analy-
sis showed that fish oil
was not efficacious in pa-
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Table 1. Methods and conclusions (Continued)
trolling for relevant
baseline characteristics.
We included a variable





tients who entered the
studies with a VT
Clarke 1998 Log-rank methods (pro-




Main The IPD review provides
a larger, more significant
estimate of treatment ef-
fect than would have
been found with a review
based solely on published
data. An IPD review can
produce very important
results that might not
have been obtainable in
any other way. Without
the ability to analyse data
on each of the women
who took part in these
randomised trials and to
update this with follow-
up information collected
after the results of some
of the trials had been
published, the important
findings would not have
come to light
D’Amico 1998 Odds ratio, stratified by
prognostic factors, were
calculated with the fixed-
effect model
Peto odds ratio (fixed-ef-
fect).
Both Firstly, this allowed
a comprehensive quality
check of the data, which,
by and large, confirmed
the validity of the aggre-
gate analysis. Secondly,
the availability of data on
individual patients per-
mitted the identification
of subgroups more likely
to benefit from treatment
Duchateau 2001 Stratified log-rank test
and Cox regression (haz-
ard ratio); to allow at
comparing with the AD
meta-analysis, also odds
ratio (at 2 and 5 years)
Odds ratio (at 2 and 5
years) and Mantel Haen-
szel test.
Main The IPD and AD re-
sults differed substan-
tially: although both the
meta-analyses showed a
significant advantage for
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Table 1. Methods and conclusions (Continued)
andMantel Haenszel test chemotherapy + loco-re-
gional treatment versus
loco-regional treatment
alone, the size of the
treatment effect varied
considerably
Fortin 1995 1) A ’narrow’ analysis on
IPD restricted to patients
from the studies included
in the AD meta-analysis
for each outcome mea-
sure, by a mixed-model




2) A ’broad validation’
analysis including IPD
from all 10 studies that
met the inclusion cri-
teria, studying all the
clinical and demographic
variables for which data
were supplied by primary
authors, and using differ-
ent analytic approaches
and more uniform out-
come measures (for this
second analysis The sites
were treated as fixed-ef-
fect)
Pooled RD with 95%
CI was calculated using
DerSimonian and Laird
method
Main The ’narrow’ IPD analy-
sis confirmed the results
of the AD meta-analysis
on the efficacy of the fish
oil treatment to improve
the tender joints count
and themorning stiffness
(no significant effect was
found for the other out-
come measures); these
main results held up also
in the broader IPD anal-
ysis. The broader IPD
analysis allowed explor-
ing the effects of a variety
of covariates
Franzosi 1997 Unclear. Unclear Main IPD meta-analysis re-
main the gold standard,
mainly when continuous
data are used and time-
dependent analyses are
the main end point
Ioannidis 1999 Study stratified propor-
tional hazard models
Pooled odds ratios Main In the absence of exten-
sive empirical evidence
in the relative validity
of meta-analysis of pub-
lished literature andmeta
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Table 1. Methods and conclusions (Continued)
Jeng 1995 Fixed-efect and random-
effects methods to ob-
tain a pooled relative live
birth ratio, adjusted for
maternal age (<3 5 years
or others) and number
of previous miscarriages
(the authors did not ex-
plain whether they ad-
justed for study effect)
Fixed-effect and
random-effects methods
to obtain a pooled rela-
tive live birth ratio
Both The IPD and AD meta-
analyses provided differ-
ent results (in particular,
AD consistently yielded
greater estimates of a
treatment benefit)
Jones 2009 Longitudinal model with
time as a factor and as
a continuous variable, as-
suming fixed treatment
effects across studies.
Two approaches were un-
dertaken. The one-step
approach simultaneously
models the IPD from
all of the studies. The
two-step approach first
fits a model to the IPD
from each study sepa-





mates across studies are
combined using a multi-
variate meta-analysis
model. taking a simplis-
tic assumption of com-
mon correlation between
observations across stud-
ies, treatment and time
points. a sensitivity anal-
ysis was also undertaken
on the assumptionof cor-
relations values of 0.8, 0.
4 and 0
Main It is preferable to ob-
tain IPD from all stud-
ies to correctly account
for the correlation be-
tween repeated observa-
tions. When IPD are not
available, the ideal ag-
gregate data are model-
based estimates of treat-
ment difference and their
variance and covariance
estimates. If covariance
estimates are not avail-
able, sensitivity analyses
should be undertaken to
investigate the robust-
ness of the results to dif-
ferent amounts of corre-
lation
Kim 2010 Meta-anal-









Main This finding was consis-
tent in both trial-level
andpatient-level analyses
Koopman 2008 Two-stage meta-analysis
of IPD. One-stage meta-
analysis of IPD including
covariate for study
Unclear Subgroup Conventionalmeta-anal-
yses do not allow proper
subgroup analyses,
whereas IPD meta-anal-
yses produce more ac-
curate subgroup effects.
Conventionalmeta-anal-
ysis showed larger and
smaller subgroup effect
estimates and wider con-
fidence intervals than
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Table 1. Methods and conclusions (Continued)
both one- and two-stage
IPD meta-analyses
le Chevalier 1996 Unclear. Unclear Both The IPD meta-analysis
shows that the advantage
of chemotherapy over
best supportive care de-
pends on the chemother-
apy regimen used
Legg 2003 Unclear. Unclear Main IPD resulted in more
precise estimates of ef-
fect with greater statisti-
cal significance and less
statistical heterogeneity
Lindley 2005 Logistic regression. Peto odds ratio Both Results on timing in-
fluence found in the
IPD meta-analyses had
already been suggested
by the Cochrane AD
meta-analysis
Lukka 2006 Unclear. Unclear Both The best evidence came
from the largest meta-
analysis based on IPD
Michiels 2005 Stratified log
rank test and the over-
all pooled HR (for each
trial, HR and variance
were derived from the
log rank statistic, then
pooled logHR were ob-
tained)
1) for each trial, logOR
and its variance were es-
timated using Yusuf et al.
method; OR of survival
at 1-year was calculated
2) a pooled ratio of me-
dian survival times (MR)
were calculated by esti-
mating a pooled logMR
weighted for variances
(inversely proportional);
variance for logMR for
each trial was estimated
using 3 different meth-
ods
Main Both OR and MR
method resulted in un-
der- and overestimation
of the treatment effect
and major loss of statisti-
cal power. Furthermore,
in 20%of trials included,
the log(MR) had an op-
posite sign to the log
(HR). OR method did
not perform much bet-
ter than the MR ra-
tio method when trans-
lated into absolute sur-
vival differences to com-
pare them with HRs
Myeloma 1998 Stratified log-rank analy-
sis
Unclear Both There is no good evi-
dence of any difference
between the results of tri-
als with IPD and those
for which published data
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Table 1. Methods and conclusions (Continued)
were used
Pignon 1992 Stratified log rank analy-
ses
Unclear Both Similar results obtained.
Rejnmark 2012 Unconditional logistic
regression
incorporating age and
sex, which we expected
a priori to contribute to
variation in mortality
Analysis on mortality
was performed using a
stratified Cox regression
model, with the clin-
ical study as stratum,
We added treatment al-
location and interaction
terms to this model too
Unclear Both Findings from IPD-MA
were supported by a trial
level meta-analysis but
there were differences
when compared to pre-
viously conducted trial
level meta-analyses
Rothwell 2011 Log-rank test (stratified
by trial) and Cox pro-
portional hazards model
stratified by trial
Unclear Main IPD are essential to de-
termine the time course
of effects on risk of cancer
and other outcomes dur-
ing trials. Crude meta-
analyses of overall num-
bers of events from trials
of different lengths with-
out stratification by pe-
riod of follow-up will be
of limited value
Saillourglenisson 2000 Stratified Hazard Ratio
was calculated.
Odds Ratio Both AD and IPD meta-anal-
ysis obtained very sim-
ilar results, demonstrat-
ing the absence of a
deleterious effect of dap-
sone on survival, al-
though IPD meta-anal-
ysis was performed only
on a subset of trials




on IPD and the meta-
regression based on AD
were also compared to




nor combining of study
interaction effects by ran-
dom effects pooling con-
sistently approximated
the multilevel model
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Table 1. Methods and conclusions (Continued)
by least-squares regres-
sion in each study and
then aggregated by meta-
analysis using a non-in-
formative prior for the
distribution of the ran-
dom interaction effects)
Shepperd 2009 Fixed-effect
model. Where at least
one event was reported
in both study groups in
a trial, we used Cox re-
gression models to calcu-
late the log hazard ratio
and its standard error for
mortality and readmis-
sion separately for each
data set. We combined




Peto odds ratio method Main






Both The results of the IPD
analysis did not differ in
important ways from the
results of the traditional
Cochrane meta-analysis
Stewart 1993 A stratified by trial Cox
regression model (fixed-
effect). In order to com-
pare IPD results to AD
results, the HR were
translated to an absolute
survival estimate at 30
months
The proportion of pa-
tients surviving at a spe-
cific time point for each
study was usually esti-
mated
from the published sur-
vival curves (HR were
mostly not presented in
the published papers. Be-
ing not binomially dis-
tributed, these data were
transformed by adjusting
(reducing) the numbers
at risk at the beginning
of the trial. The estimates
for each trial obtained
in this way were pooled
by the modified Mantel-
Haensezel method (OR)
Main The AD-MA gave a re-
sult of greater statistical
significance and an esti-
mate of absolute treat-
ment effect 3 times as
large as the IPD-MA
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Table 1. Methods and conclusions (Continued)
. In order to compare
IPDresults toADresults,
the OR were translated
to an absolute survival
estimate at 30 months.
For the additional analy-
ses made in order to in-
vestigate the effect of po-
tential sources of bias in
an ADMA, the OR were
calculated using the IPD
from AOCTG database
and then pooled
Szczech 1998 Using data from the pub-
lished reports, we calcu-
lated the rate ratios of al-
lograft failure by use of
a discrete-time version of
the proportional hazards
model for both the subset
of studies for which indi-
vidual patient-level data
were available and the
subset for which data
were unavailable
Using data from the pub-
lished reports, we calcu-
lated the rate ratios of al-
lograft failure by use of
a discrete-time version of
the proportional hazards
model for both the subset
of studies for which indi-
vidual patient-level data
were available and the
subset for which data
were unavailable
Main Even when follow-up
is incomplete, individ-
ual patient-level data can
be analysed with survival
analysis techniques that
yield estimates of true
rates of failure over time
rather than less informa-
tive estimates of risk. In
addition, by using indi-
vidual patient-level data
extended beyond the fol-
low-up in the published
literature, meta-analyses
such as this one can
evaluate long-term sur-
vival. We were able to
evaluate potential predic-
tors of allograft survival,
such as recipient ethnic-
ity and panel reactive an-
tibody levels; this was not
possible in our previous
meta-analysis, when used
published data. Finally,
use of individual patient-
level data allowed us to
perform subgroup analy-
ses that were not possi-
ble by using original pub-
lished analyses
Teramukai 2004 Model 1: Cox regression
model, stratified by trial
(fixed effect), including
Meta-regressionwith risk
ratio (RR) as dependent
variable (only graphical
Subgroup Meta-regression gave a
greater P value for in-
teraction term than the
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Table 1. Methods and conclusions (Continued)
interaction term ’treat-
ment x stage’. Model
2: Fixed-effects exponen-
tial risk model where
the survival outcome was
changed to a binary out-
come (alive or dead at the
end of the study); inter-
action term ’treatment x
stage’ was included
results are shown for AD-
MA)
IPD-MA (both the MA
gave non statistically sig-
nificant results). When
excluding two studies
(including only stage I
patients), the direction of
the effect found by meta-
regression was inverted




analysis to pool the ab-
solute risk difference in
each (sub)trial, either
two- or three-level mod-
els. Meta-regression for
the effect of the time de-
lay
Both AD meta-analyses (clas-
sical and bayesian) and
IPD meta-analysis gave
very similar results. It is
preferable to model in-
dividual participant out-
come data directly rather
than summary statistics
to avoid the assump-
tions that have to be
made regarding the sum-
mary statistics (of nor-
mality and known vari-
ance). Furthermore, in-
dividual participant level
covariates can be intro-
duced to study potential
treatment interactions
Tierney 2001 Unclear Unclear Main Where events happen
quickly, HRs from pub-
lished data and IPDwere
very similar, although
the published data were
less convincing. How-
ever, where events hap-
pen over a prolonged pe-
riod, the HR of the pub-
lished data was a poorer
approximation of both
its IPD equivalent and
the full IPD analysis
Tonia 2011 Unclear Unclear Main This was a review of
meta-analyses.With IPD
the limitations of liter-
ature-based meta-analy-
ses, that have to analyse
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Table 1. Methods and conclusions (Continued)
data as reported in the lit-
erature with inconsisten-
cies across studies, can be
overcome




Both AD analysis can be useful
in some circumstances.
All analyses agreed in
overall conclusion and
suggested that risk of
death was significantly
reduced in chemother-
apy group. estimates of
heterogeneity differ be-
tween IPD and AD
Tudur Smith 2005 Fixed-effect and ran-
dom-effects Cox regres-
sion model stratified by
trial including covariates





Both The availability of IPD
allowed a thorough in-
vestigation into the main
effects of each covari-
ate which was not pos-
sible using meta-regres-
sion of AD. Age as a
potential cause of het-
erogeneity is detected by
both AD and IPD regres-
sion models. Time from
first ever seizure to ran-
domisation is only iden-
tified by some AD mod-
els. A more thorough
explanation of hetero-
geneity is obtained from
the model using IPD.
A pragmatic comparison
of results using IPD vs.
results using extracted
AD was not possible for
this example as sufficient
data were unavailable di-
rectly from trial reports.
For the epilepsy exam-
ple, the clinical inter-
pretation obtained from
the final Cox regression
models would not have
been discovered without
IPD. For the empiri-
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Table 1. Methods and conclusions (Continued)
cal comparisonpresented
in the current paper in-
volving a small number
of trials, but still reflec-
tive of many meta-anal-
yses in practice, the re-
sults suggest that meta-
regression using AD can
be accurate if there is
evidence for a within
study treatment by co-
variate interaction and
sufficient between trial
variation for the aggre-
gate value of the covari-
ate. Departures from this
condition could mean
that meta-regression re-
sults using AD are un-
reliable. IPD should be
used whenever possible





the number of trials in
the meta-analysis is small
and AD approaches are
likely to become increas-
ingly more uncertain.
Furthermore, if time-to-
event outcomes are of in-
terest, IPD can be ex-
tremely valuable as a re-
sult of limitations re-
porting appropriate sum-
mary data
Turner 2000 Multilevel modelling for
binary outcome (based
on logistic modelling),
with fixed trial effects
(using standard logistic
regression for fixed treat-
ment effects and addi-
tional iterative estima-
tion procedures for ran-
dom treatment effects)
Standard meth-




Main For the first example,
“The fixed and random
effects estimates from in-
dividual data methods all
differed noticeably from
the corresponding sum-
mary data estimates; each
of the latter indicates
a smaller treatment ef-
fect than its counter-
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Table 1. Methods and conclusions (Continued)
and random trial effects part”. For the second ex-
ample: “differences be-
tween summary and IP
data estimates of the lo-
gOR and between-trial
variance were generally
smaller than in the first
example”
Vansteenkiste 2012 Cox proportional haz-
ards models
stratified by study.
Random-effects Both By including IPD from
both published and un-
published
sources, the meta-analy-
sis study avoids some of
these limitations (publi-
cation bias)






Main Fitting fixed-effect and
random-effects meta-
analysis models to trials
of counselling in primary
care, adopting summary-
data and IPD approaches
and allowing for these ef-
fects, had minimal im-
pact on the pooled es-
timate and its standard
error. Collection of the
IPD is made attractive by
the potential of meta-re-
gression analyses for ex-
ploring trial-level, ther-
apist-level and patient-
level predictors of the
treatment effect and of
the random-effects
Williamson 2000 Stratified log rank analy-
ses
Extracting estimates of
the log hazard ratio from
publications and com-
bined using stratified log
rank analysis
Main More empirical data are
needed to answer the
question whether the ex-
tra investment needed
for IPD is worthwhile
Abbreviations: AD: Aggregate data, AD-MA: Aggregate data meta-analysis, AOCTG: Advanced Ovarian Cancer Trialists Group,
BP: Blood pressure, IPD: IPD: Individual participant data, PRA: panel reactive antibodies, RD: risk difference, REML: restricted
maximum likelihood, VT: ventricular tachycardia
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Study quality* Comparison of
IPD-MA and AD-
MA










Berlin 2002 Yes A Yes No Yes
Best 2000 Yes A Yes No Yes
Beveridge 2015 Yes A No No Yes
Brouwer 2009 Yes B (Insufficient in-
formation)
No No Yes
Clarke 1998 Yes A Yes No Yes
D’Amico 1998 Yes A Yes No Yes
Duchateau 2001 Yes A Yes No Yes
Fortin 1995 Yes A Yes No Yes
Franzosi 1997 Unclear B (Insufficient in-
formation)
Yes Unclear Unclear
Ioannidis 1999 Yes A No Yes Yes
Jeng 1995 Yes A Yes No Yes
Jones 2009 Yes A Yes No Yes
Kim 2010 Yes A No No Yes
Koopman 2008 Yes A Yes Yes Yes
le Chevalier 1996 Yes B (Statistical meth-
ods unclear)
Yes Yes Yes
Legg 2003 Unclear B (Insufficient in-
formation)
Yes Yes Unclear
Lindley 2005 Yes A No No Yes
Lukka 2006 Yes B (Statistical meth-
ods unclear)
No Yes Yes
Michiels 2005 Yes A Yes No Yes
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Table 2. Summary of quality (Continued)
Myeloma 1998 Yes A No Unclear Yes
Pignon 1992 Yes A Yes Yes Yes
Rejnmark 2012 Yes A No Yes Yes
Rothwell 2011 Yes A No No Yes
Saillourglenisson
2000
Yes A No No Yes
Schmid 2004 Yes A Yes No Yes
Shepperd 2009 Yes A No No Yes
Spooner 1998 Yes B (Insufficient in-
formation)
Yes Yes Yes
Stewart 1993 Yes A Yes Unclear Yes
Szczech 1998 Yes A No No Yes
Teramukai 2004 Yes A Yes No Yes
Thompson 2001 Yes A Yes Yes Yes
Tierney 2001 Yes B (Insufficient in-
formation)
Yes Yes Yes
Tonia 2011 No B (Insufficient in-
formation)
No Yes No
Tudur 2001 Yes A No No Yes
Tudur Smith 2005 Yes A Yes No Yes
Turner 2000 Yes A Yes No Yes
Vansteenkiste 2012 Yes B (Insufficient in-
formation)
No No Yes
Walwyn 2015 Yes B (Insufficient in-
formation)
No No Yes
Williamson 2000 Yes A No Yes Yes
* A = No important flaws; B = Possibly important flaws; C = Major flaws
Abbreviations: AD: Aggregate data, AD-MA: Aggregate data meta-analysis, IPD: Individual participant data, IPD-MA: Individual
participant data meta-analysis
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Table 3. Comparison of statistical significance (at 5% two-sided level) of IPD-MA and AD-MA across 190 comparisons (main
effect and effect modifier analyses)
AD-MA
Not significant Significant* Total
IPD-MA Not significant 77 (41) 10 (5) 87 (46)
Significant* 28 (15) 75 (39) 103 (54)
Total 105 (55) 85 (45) 190 (100)
Abbreviations: AD: Aggregate data, AD-MA: Aggregate data meta-analysis, IPD: Individual participant data, IPD-MA: Individual
participant data meta-analysis
Table entries are number (%) of comparisons.
*Statistical significance determined using standardised effect estimates for 174 comparisons where effect estimates are Hazard Ratio,
Risk Ratio, Odds Ratio, Rate Ratio and Mean Difference (plotted in Figure 4 and Figure 5), and using the data as presented for the
remaining 16 comparisons (e.g. a study presented results as a regression coefficient with P value).
Table 4. Comparison of statistical significance (at 5% two-sided level) of IPD-MA and AD-MA across 190 comparisons
according to type of analysis
AD-MA
Main effect analysis Not significant Significant* Total
IPD-MA Not significant 42 (29) 6 (4) 48 (33)
Significant* 25 (17) 71 (49) 96 (67)
Total 67 (47) 77 (53) 144 (100)
Treatment effect modifier
analysis
Not significant Significant* Total
IPD-MA Not significant 35 (76) 4 (9) 39 (85)
Significant* 3 (7) 4 (9) 7 (16)
Total 38 (83) 8 (17) 46 (100)
Abbreviations: AD: Aggregate data, AD-MA: Aggregate data meta-analysis, IPD: Individual participant data, IPD-MA: Individual
participant data meta-analysis
Table entries are number (%) of comparisons.
*Statistical significance determined using standardised effect estimates for 174 comparisons where effect estimates are Hazard Ratio,
Risk Ratio, Odds Ratio, Rate Ratio and Mean Difference (plotted in Figure 4 and Figure 5), and using the data as presented for the
remaining 16 comparisons (e.g. a study presented results as a regression coefficient with P value).
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Table 5. Comparison of significance (at 5% two-sided level) of IPD-MA and AD-MA across 174 comparisons according to
similarity of data and treatment effect type (main effect and effect modifier analyses)
AD-MA
Same trials and patients,
same treatment effect
Not significant Significant* Total
IPD-MA Not significant 28 (47) 5 (8) 33 (56)
Significant* 4 (7) 22 (37) 26 (44)
Total 32 (54) 27 (46) 59 (100)
Same trials and patients, dif-
ferent treatment effect
IPD-MA Not significant 8 (22) 1 (3) 9 (25)
Significant* 10 (28) 17 (47) 27 (75)
Total 18 (50) 18 (50) 36 (100)
Different trials and patients,
same treatment effect
IPD-MA Not significant 30 (54) 3 (5) 33 (59)
Significant* 9 (16) 14 (25) 23 (41)
Total 39 (70) 17 (30) 56 (100)
Different trials and patients,
different treatment effect
IPD-MA Not significant 11 (28) 1 (3) 12 (31)
Significant* 5 (13) 22 (56) 27 (69)
Total 16 (41) 23 (59) 39 (100)
Abbreviations: AD: Aggregate data, AD-MA: Aggregate data meta-analysis, IPD: Individual participant data, IPD-MA: Individual
participant data meta-analysis
Table entries are number (%) of comparisons.
*16 comparisons with insufficient numerical data regarding number of patients have been excluded from this table
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Table 6. Agreement
Analysis (n) Average Difference (IPD-MA -AD-MA) 95% Limits of Agreement
1.1. Difference in Z scores MA only (144) -0.22 -2.84 to 2.40
1.2. Difference in Z scores MR only (46) 0.08 -2.26 to 2.43
1.3. Difference in Z scores MA only ratio
effects (115)
-0.34 -2.87 to 2.19
1.4. Difference in Z scores MR only ratio
effects (25)
0.42 -1.97 to 2.80
1.5. Difference in Z scores MA only differ-
ence effects (28)
0.20 -2.64 to 3.05
1.6. Difference in Z scores MR only differ-
ence effects (19)
-0.44 -2.46 to 1.57
2.1. Difference in Log ratio effect estimates
MA only (115)
-0.004 -0.36 to 0.35
2.2. Difference in Log ratio effect estimates
MR only (25)
-0.05 -0.78 to 0.69
3.1. Log ratio effect standard errors MA
only (115)
-0.015 -0.14 to 0.11
3.2. Log ratio effect standard errors MR
only (25)
0.012 -0.55 to 0.57
MA: main effect analyses, MR: interaction effect analyses
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A P P E N D I C E S
Appendix 1. Search Strategy




Reviewmethodology - data collection - individual patient data - general meth-
ods
Review methodology - data collection - individual patient data - IPD vs other
types of meta-analysis




[These terms were combined with the Boolean OR]
CENTRAL
(2006, Issue 2)
#1 (individual next patient next data)
#2 ((individual next patient*) near data)
#3 ((individual next patient*) near report*)
#4 ((individual next patient*) near outcome*)
#5 ipd
#6 (#1 or #2 or #3 or #4 or #5)
OvidWeb MEDLINE
(1966 to May Week 5 2006)
1 individual patient data.ti,ab.
2 individual patient report$.ti,ab.
3 individual patient outcome$.ti,ab.
4 (individual patient$ adj6 data).ti,ab.
5 (individual patient$ adj6 report$).ti,ab.




(1980 to 2004 Week 20)
1 individual patient data.ti,ab.
2 individual patient report$.ti,ab.
3 individual patient outcome$.ti,ab.
4 (individual patient$ adj6 data).ti,ab.
5 (individual patient$ adj6 report$).ti,ab.
6 (individual patient$ adj6 outcome$).ti,ab.
7 ipd.ti,ab.
8 or/1-7
Search undertaken on May 14 2009
51Individual participant data meta-analyses compared with meta-analyses based on aggregate data (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search strategies: Individual patient data meta-analyses compared with meta-analyses based on aggregate data.
MEDLINE OvidSP (MEDLINE In-Process & Other Non-indexed citations and MEDLINE (R)) (1950 to Week 2 May 2009);
Embase OvidSP (1980 to Week 19 2009) searched 14 May 2009
1 (individual patient$ adj6 data).tw.
2 (individual patient$ adj6 report$).tw.
3 (individual patient$ adj6 outcome$).tw.
4 (individual patient$ adj6 level$).tw.
5 ipd.tw.
6 (individual subject$ adj6 data).tw.
7 (individual subject$ adj6 report$).tw.
8 (individual subject$ adj6 outcome$).tw.
9 (individual subject$ adj6 level$).tw.
10 (raw patient$ adj6 data).tw.
11 (raw data adj6 patient$).tw.
12 (raw data adj6 individual$).tw.
13 (raw data adj6 subject$).tw.
14 (raw data adj6 participant$).tw.
15 (individual participant$ adj6 data).tw.
16 (individual participant$ adj6 report$).tw.
17 (individual participant$ adj6 outcome$).tw.
18 (individual participant$ adj6 level$).tw.
19 or/1-18
20 remove duplicates from 19
The Cochrane Library Issue 2 2009 (includes Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effec-
tiveness, CENTRAL, Cochrane Methodology Register, HTA database, NHS Economic Evaluations Database) - searched 14 May
2009
#1 (individual next patient*):ti,ab near6 data:ti,ab
#2 (individual next patient*):ti,ab near6 report*:ti,ab
#3 (individual next patient*):ti,ab near6 outcome*:ti,ab
#4 (individual next patient*) near6 level*:ti,ab
#5 ipd:ti,ab
#6 (individual next subject*):ti,ab near6 data:ti,ab
#7 (individual next subject*):ti,ab near6 report*:ti,ab
#8 (individual next subject*):ti,ab near6 outcome*:ti,ab
#9 (individual next subject*):ti,ab near6 level*:ti,ab
#10 (raw next patient*):ti,ab near6 data:ti,ab
#11 (raw next data):ti,ab near6 patient*:ti,ab
#12 (raw next data):ti,ab near6 individual*:ti,ab
#13 (raw next data):ti,ab near6 subject*:ti,ab
#14 (raw next data):ti,ab near6 participant*:ti,ab
#15 (individual next participant*):ti,ab near6 data:ti,ab
#16 (individual next participant*):ti,ab near6 report*:ti,ab
#17 (individual next participant*):ti,ab near6 outcome*:ti,ab
#18 (individual next participant*):ti,ab near6 level*:ti,ab
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
Search undertaken on Jan 7 2016
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Search strategies: Individual patient data meta-analyses compared with meta-analyses based on aggregate data.
MEDLINE OvidSP (MEDLINE In-Process & Other Non-indexed citations and MEDLINE (R)) (1950 to Week 1 January 2016);
Embase OvidSP (1980 to Week 1 2016) searched 7 January 2016
1 (individual patient$ adj6 data).tw.
2 (individual patient$ adj6 report$).tw.
3 (individual patient$ adj6 outcome$).tw.
4 (individual patient$ adj6 level$).tw.
5 ipd.tw.
6 (individual subject$ adj6 data).tw.
7 (individual subject$ adj6 report$).tw.
8 (individual subject$ adj6 outcome$).tw.
9 (individual subject$ adj6 level$).tw.
10 (raw patient$ adj6 data).tw.
11 (raw data adj6 patient$).tw.
12 (raw data adj6 individual$).tw.
13 (raw data adj6 subject$).tw.
14 (raw data adj6 participant$).tw.
15 (individual participant$ adj6 data).tw.
16 (individual participant$ adj6 report$).tw.
17 (individual participant$ adj6 outcome$).tw.
18 (individual participant$ adj6 level$).tw.
19 or/1-18
20 remove duplicates from 19
The Cochrane Library Issue 1 2016 (includes Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effec-
tiveness, CENTRAL, Cochrane Methodology Register, HTA database, NHS Economic Evaluations Database) - searched 7 January
2016
#1 (individual next patient*):ti,ab near6 data:ti,ab
#2 (individual next patient*):ti,ab near6 report*:ti,ab
#3 (individual next patient*):ti,ab near6 outcome*:ti,ab
#4 (individual next patient*) near6 level*:ti,ab
#5 ipd:ti,ab
#6 (individual next subject*):ti,ab near6 data:ti,ab
#7 (individual next subject*):ti,ab near6 report*:ti,ab
#8 (individual next subject*):ti,ab near6 outcome*:ti,ab
#9 (individual next subject*):ti,ab near6 level*:ti,ab
#10 (raw next patient*):ti,ab near6 data:ti,ab
#11 (raw next data):ti,ab near6 patient*:ti,ab
#12 (raw next data):ti,ab near6 individual*:ti,ab
#13 (raw next data):ti,ab near6 subject*:ti,ab
#14 (raw next data):ti,ab near6 participant*:ti,ab
#15 (individual next participant*):ti,ab near6 data:ti,ab
#16 (individual next participant*):ti,ab near6 report*:ti,ab
#17 (individual next participant*):ti,ab near6 outcome*:ti,ab
#18 (individual next participant*):ti,ab near6 level*:ti,ab
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
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Does the study include both IPD and aggregate data meta-analyses for the same comparison?
Is it a comparison of meta-analyses of RCTs?
Does the study compare the results of the IPD and the aggregate data meta-analyses?
Was a comparison of IPD and aggregate data meta-analyses one of the main aims of the study?
What treatments/interventions are compared in the meta-analyses?
Type of disease
What types of patients are studied in the meta-analyses?
What is the outcome measure of the meta-analyses?
Were the meta-analyses done by independent researchers?
Aggregated data obtained (published reports/unclear/neither/trialists/other)
In your opinion are the inclusion criteria for the IPD and aggregate data meta-analyses similar?
Are the same outcome definitions used for the IPD and aggregate data meta-analyses?
What methods were used for analysis of IPD?
What methods were used for analysis of AD?
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(Continued)
What were the main conclusions of the study about the comparison of IPD and aggregate data meta-analysis?
What reasons (if any) were given for any differences?
Would you describe the quality of this study as (A = No important flaws, B = Possibly important flaws, C = Major flaws)
If B or C please describe flaws
Is further information required from the authors?
Data Included in IPD Analysis - All trials
Data Included in IPD Analysis - Published trials only
Data Included in IPD Analysis - Unpublished trials only
Data Included in IPD Analysis - Updated data
Data Included in IPD Analysis - Including excluded participants
Data Included in AD Analysis - All trials
Data Included in AD Analysis - Published trials only
Data Included in AD Analysis - Unpublished trials only
Data Included in AD Analysis - Updated data
Data Included in AD Analysis - Including excluded participants
Other Items
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 9, 2016
Date Event Description
27 December 2007 Amended Converted to new review format.
20 February 2007 New citation required and major changes Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol for this review planned to explore separately comparisons based on aggregate data extracted from published reports
[IPD-MA versus AD-MA published], aggregate data collected from the responsible trialists [IPD-MA versus AD-MA with trialists’
aggregate data], and those based on a combination of aggregate data collected from the responsible trialists and aggregate data extracted
from published reports [IPD versus best available aggregate data]. However, due to reporting limitations further work is required to
contact authors and request additional analyses to explore fully the effects of differing levels of aggregate data. Therefore, this review
summarises comparisons made between IPD-MA and AD-MA of all types and further important information may be uncovered by
seeking additional information, which is planned in a future update of this review.
We did not compare the cost and resource implications of IPD-MA and AD-MA because this was rarely mentioned in the studies.
However, this is an important consideration for researchers and further data are required to examine this question.
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